tradingkey.logo
Search
Markets
Watchlist
News
Analysis
Tools
Stock Screener
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo
Search

Regeneron Pharmaceuticals Inc

REGN
Add to Watchlist
651.870USD
+0.690+0.11%
Close 07-23 16:00（ET）Quotes delayed by 15 min
68.45BMarket Cap
15.34P/E TTM

Regeneron Pharmaceuticals Inc

651.870
+0.690+0.11%
Overview
Financials
Discussions
Analysis
Company
Financial SummaryIncome StatementBalance SheetCash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial SummaryIncome StatementBalance SheetCash Flow Statement

REGN Financials

See Regeneron Pharmaceuticals Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.

Regeneron Pharmaceuticals Inc Earnings Date

Latest Release
Jul 30, 2026
EPS / Forecast
--/10.32
Revenue / Forecast
--/3.82B
See Upcoming Earnings >>
Period
FY2025 Earnings
Revenue(YoY)
14.34B
0.99%
EPS(YoY)
43.07
5.31%
Analyst Rating
BUY
2026/07/23
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
Financial Indicators
EPS
-7.74%6.99
-3.95%8.19
13.64%14.09
-0.07%13.24
13.16%7.58
-21.74%8.53
30.81%12.40
46.40%13.25
-12.29%6.70
-2.77%10.90
--9.48
--9.05
--7.64
--11.21
--29.30
----
----
----
----
----
Revenue
19.04%3.61B
2.51%3.88B
0.90%3.75B
3.62%3.68B
-3.70%3.03B
10.33%3.79B
10.65%3.72B
12.32%3.55B
-0.54%3.15B
0.58%3.43B
14.53%3.36B
10.53%3.16B
6.64%3.16B
-31.05%3.41B
-14.96%2.94B
-44.40%2.86B
17.26%2.97B
104.37%4.95B
50.51%3.45B
163.24%5.14B
Net Profit
-10.08%727.20M
-7.97%844.60M
8.91%1.46B
-2.84%1.39B
12.01%808.70M
-20.86%917.70M
33.02%1.34B
47.90%1.43B
-11.71%722.00M
-3.13%1.16B
-23.40%1.01B
13.65%968.40M
-15.99%817.80M
-46.29%1.20B
-19.39%1.32B
-72.50%852.10M
-12.71%973.50M
93.96%2.23B
93.82%1.63B
245.36%3.10B
Net Margin
-24.46%20.17%
-10.22%21.74%
11.22%40.07%
-6.24%37.86%
16.31%26.70%
-28.27%24.22%
20.22%36.03%
31.68%40.38%
-11.23%22.96%
-3.69%33.77%
--29.97%
--30.66%
--25.86%
--35.06%
--35.87%
----
----
----
----
----
Gross Margin
-3.82%81.43%
1.12%89.40%
-0.80%86.11%
-1.03%85.58%
-1.78%84.67%
0.55%88.41%
-0.25%86.80%
-0.82%86.46%
0.79%86.21%
-0.96%87.92%
--87.02%
--87.18%
--85.53%
--88.78%
--89.51%
----
----
----
----
----
Debt to assets ratio
-8.08%6.62%
-6.85%6.67%
-6.74%6.74%
-5.53%7.08%
-8.41%7.20%
-12.34%7.16%
-14.05%7.22%
-15.00%7.49%
-12.49%7.87%
-11.64%8.17%
--8.40%
--8.81%
--8.99%
--9.25%
--9.76%
----
----
----
----
----
Income Statement
Revenue
19.04%3.61B
2.51%3.88B
0.90%3.75B
3.62%3.68B
-3.70%3.03B
10.33%3.79B
10.65%3.72B
12.32%3.55B
-0.54%3.15B
0.58%3.43B
14.53%3.36B
10.53%3.16B
6.64%3.16B
-31.05%3.41B
-14.96%2.94B
-44.40%2.86B
17.26%2.97B
104.37%4.95B
50.51%3.45B
163.24%5.14B
Operating profit
23.31%744.80M
-6.48%1.07B
-10.76%1.11B
-1.68%1.09B
-21.94%604.00M
3.67%1.15B
2.70%1.24B
9.01%1.11B
-22.84%773.80M
-17.16%1.11B
-4.42%1.21B
-22.22%1.02B
-25.42%1.00B
-54.24%1.33B
-31.41%1.27B
-60.96%1.31B
20.84%1.34B
149.82%2.92B
75.41%1.85B
351.47%3.35B
Net Profit
-10.08%727.20M
-7.97%844.60M
8.91%1.46B
-2.84%1.39B
12.01%808.70M
-20.86%917.70M
33.02%1.34B
47.90%1.43B
-11.71%722.00M
-3.13%1.16B
-23.40%1.01B
13.65%968.40M
-15.99%817.80M
-46.29%1.20B
-19.39%1.32B
-72.50%852.10M
-12.71%973.50M
93.96%2.23B
93.82%1.63B
245.36%3.10B
Balance Sheet
Current assets
3.63%18.21B
-3.42%18.02B
-7.00%17.98B
-11.65%16.86B
-6.89%17.57B
-4.20%18.66B
3.75%19.33B
12.76%19.08B
11.60%18.87B
22.63%19.48B
20.78%18.63B
8.97%16.92B
18.20%16.91B
13.34%15.88B
12.00%15.43B
16.44%15.53B
42.28%14.31B
43.31%14.01B
51.42%13.78B
69.69%13.34B
Total current liabilities
43.21%5.11B
10.75%4.37B
20.87%4.43B
4.51%3.67B
-0.40%3.57B
15.22%3.94B
1.73%3.66B
13.02%3.51B
15.51%3.58B
8.98%3.42B
24.99%3.60B
2.32%3.10B
3.08%3.10B
-20.12%3.14B
-22.49%2.88B
-18.71%3.03B
-6.53%3.01B
45.79%3.93B
58.90%3.71B
0.81%3.73B
Total assets
8.85%40.87B
7.41%40.56B
7.28%40.17B
5.91%38.22B
9.24%37.55B
14.15%37.76B
16.41%37.44B
17.71%36.09B
14.34%34.37B
13.23%33.08B
16.21%32.16B
12.69%30.66B
14.08%30.06B
14.86%29.21B
16.92%27.68B
26.62%27.21B
48.26%26.35B
48.19%25.43B
47.17%23.67B
48.91%21.49B
Total liabilities
15.78%9.45B
10.66%9.30B
13.50%9.21B
5.07%8.28B
10.56%8.16B
18.27%8.41B
11.81%8.12B
18.70%7.88B
12.40%7.38B
8.50%7.11B
16.35%7.26B
1.87%6.64B
2.03%6.56B
-1.73%6.55B
-2.72%6.24B
2.51%6.52B
11.02%6.43B
8.60%6.67B
7.64%6.41B
18.38%6.36B
Total equity
6.93%31.42B
6.48%31.26B
5.56%30.96B
6.14%29.94B
8.88%29.39B
13.02%29.35B
17.75%29.33B
17.44%28.21B
14.88%26.99B
14.60%25.97B
16.17%24.90B
16.10%24.02B
17.98%23.50B
20.75%22.66B
24.23%21.44B
36.76%20.69B
66.27%19.91B
70.23%18.77B
70.44%17.26B
67.02%15.13B
Cash Flow Statement
Net operating income
3.23%1.08B
-7.29%1.17B
25.36%1.62B
223.28%1.14B
-30.90%1.05B
15.89%1.26B
15.88%1.29B
-65.38%354.00M
10.60%1.51B
-36.64%1.09B
77.18%1.11B
81.15%1.02B
-34.93%1.37B
-27.51%1.72B
-81.58%628.90M
-9.94%564.40M
214.39%2.10B
92.73%2.37B
1442.35%3.41B
-33.57%626.70M
Net investment
-166.24%-428.90M
-37.16%220.30M
29.86%-402.90M
-96.34%-1.09B
138.38%647.50M
629.61%350.60M
-15.74%-574.40M
76.66%-557.20M
-615.78%-1.69B
96.44%-66.20M
-358.09%-496.30M
-476.69%-2.39B
86.18%-235.70M
7.70%-1.86B
107.89%192.30M
-429.01%-413.90M
-61.03%-1.71B
-559.90%-2.01B
-214.36%-2.44B
-91.34%125.80M
Net financing
26.35%-802.20M
31.30%-780.10M
-13.23%-717.90M
-135.98%-1.13B
-2412.53%-1.09B
-154.54%-1.14B
-55.66%-634.00M
22.16%-478.10M
114.60%47.10M
-80.17%-446.10M
43.82%-407.30M
-507.52%-614.20M
-598.45%-322.50M
72.69%-247.60M
-288.12%-725.00M
14.47%-101.10M
117.66%64.70M
-196.95%-906.60M
-37.03%385.40M
95.48%-118.20M

FAQs

What is the total revenue of Regeneron Pharmaceuticals Inc?

According to Regeneron Pharmaceuticals Inc's FY2025 earnings report, its total revenue reached 14.34B, with a year-on-year change of 14.20B.

What are the current assets of Regeneron Pharmaceuticals Inc?

According to Regeneron Pharmaceuticals Inc's FY2025 earnings report, its current assets were 18.02B, with a year-on-year change of -3.42.

What are the total assets of Regeneron Pharmaceuticals Inc?

According to Regeneron Pharmaceuticals Inc's FY2025 earnings report, its total assets of Regeneron Pharmaceuticals Inc were 40.56B, with a year-on-year change of 7.41.

What are the total liabilities of Regeneron Pharmaceuticals Inc?

According to Regeneron Pharmaceuticals Inc's FY2025 earnings report, its total liabilities of Regeneron Pharmaceuticals Inc were 9.30B, with a year-on-year change of 10.66.

What is the total equity of Regeneron Pharmaceuticals Inc?

According to Regeneron Pharmaceuticals Inc's FY2025 earnings report, its total equity of Regeneron Pharmaceuticals Inc was 31.26B, with a year-on-year change of 6.48.

What is the net operating income of Regeneron Pharmaceuticals Inc?

According to Regeneron Pharmaceuticals Inc's FY2025 earnings report, its net operating income of Regeneron Pharmaceuticals Inc was 3.87B, with a year-on-year change of -9.28.

What is the net investment of Regeneron Pharmaceuticals Inc?

According to Regeneron Pharmaceuticals Inc's FY2025 earnings report, its net investment of Regeneron Pharmaceuticals Inc was -629.10M, with a year-on-year change of 74.51.

What is the net financing of Regeneron Pharmaceuticals Inc?

According to Regeneron Pharmaceuticals Inc's FY2025 earnings report, its net financing of Regeneron Pharmaceuticals Inc was -3.72B, with a year-on-year change of -68.84.

What is the Earnings Per Share (EPS) of Regeneron Pharmaceuticals Inc?

According to Regeneron Pharmaceuticals Inc's FY2025 earnings report, its Earnings Per Share (EPS) was 43.07, with a year-on-year change of 5.31.

What is the net income of Regeneron Pharmaceuticals Inc?

According to Regeneron Pharmaceuticals Inc's FY2025 earnings report, its net income was 4.50B, with a year-on-year change of 2.09.

What is the net margin of Regeneron Pharmaceuticals Inc?

According to Regeneron Pharmaceuticals Inc's FY2025 earnings report, its net profit margin was 31.72, with a year-on-year change of 2.09.

What is the gross margin of Regeneron Pharmaceuticals Inc?

According to Regeneron Pharmaceuticals Inc's FY2025 earnings report, its gross margin was 86.56, with a year-on-year change of -0.52.

What is the debt-to-asset ratio of Regeneron Pharmaceuticals Inc?

According to Regeneron Pharmaceuticals Inc's FY2025 earnings report, its debt-to-asset ratio was 6.67, with a year-on-year change of -6.85.

What is the Return on Equity (ROE) of Regeneron Pharmaceuticals Inc?

According to Regeneron Pharmaceuticals Inc's FY2025 earnings report, its Return on Equity (ROE) was 15.01, with a year-on-year change of -5.89.

What is the Return on Assets (ROA) of Regeneron Pharmaceuticals Inc?

According to Regeneron Pharmaceuticals Inc's FY2025 earnings report, its Return on Assets (ROA) was 11.62, with a year-on-year change of -6.74.

What is the operating profit of Regeneron Pharmaceuticals Inc?

According to Regeneron Pharmaceuticals Inc's FY2025 earnings report, its operating profit was 3.87B, with a year-on-year change of -9.28.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.
General Terms of Use
Privacy Policy
Cookie Policy